UI Hospitals and Clinics
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
Participants in this research study have been diagnosed with advanced stage non-small cell lung cancer and are currently receiving chemotherapy. The purpose of this study is to determine the safety of a drug called darbepoetin alfa. Approximately 3000 people will be enrolled in this study worldwide. Study involvement will last until the conclusion of the study.
Karen Parrott, 319-353-6347
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.